An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI.

deep learning diagnosis dynamic susceptibility contrast glioblastoma lymphoma metastasis neuro-oncology perfusion MRI

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
05 Mar 2024
Historique:
received: 30 08 2023
revised: 16 11 2023
accepted: 15 02 2024
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 12 3 2024
Statut: aheadofprint

Résumé

Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI.

Identifiants

pubmed: 38471504
pii: S2666-3791(24)00108-3
doi: 10.1016/j.xcrm.2024.101464
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101464

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Alonso Garcia-Ruiz (A)

Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Albert Pons-Escoda (A)

Radiology Department, Bellvitge University Hospital, 08907 Barcelona, Spain; Neuro-Oncology Unit, Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), 08907 Barcelona, Spain.

Francesco Grussu (F)

Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Pablo Naval-Baudin (P)

Radiology Department, Bellvitge University Hospital, 08907 Barcelona, Spain.

Camilo Monreal-Aguero (C)

Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Gretchen Hermann (G)

Radiation Medicine Department and Applied Sciences, University of California, San Diego, La Jolla, CA 92093, USA.

Roshan Karunamuni (R)

Radiation Medicine Department and Applied Sciences, University of California, San Diego, La Jolla, CA 92093, USA.

Marta Ligero (M)

Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Antonio Lopez-Rueda (A)

Radiology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.

Laura Oleaga (L)

Radiology Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.

M Álvaro Berbís (MÁ)

Radiology Department, HT Medica, Hospital San Juan de Dios, 14012 Cordoba, Spain.

Alberto Cabrera-Zubizarreta (A)

Radiology Department, HT Medica, 23008 Jaen, Spain.

Teodoro Martin-Noguerol (T)

Radiology Department, HT Medica, 23008 Jaen, Spain.

Antonio Luna (A)

Radiology Department, HT Medica, 23008 Jaen, Spain.

Tyler M Seibert (TM)

Radiation Medicine Department and Applied Sciences, University of California, San Diego, La Jolla, CA 92093, USA; Radiology Department, University of California, San Diego, La Jolla, CA 92093, USA; Bioengineering Department, University of California, San Diego, La Jolla, CA 92093, USA.

Carlos Majos (C)

Radiology Department, Bellvitge University Hospital, 08907 Barcelona, Spain; Neuro-Oncology Unit, Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), 08907 Barcelona, Spain.

Raquel Perez-Lopez (R)

Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. Electronic address: rperez@vhio.net.

Classifications MeSH